Will Latest Dabigatran Data Finally Topple Warfarin?

NEW ORLEANS - Boehringer Ingelheim's dabigatran etexilate had comparable efficacy and significantly lower or comparable bleeding rates to warfarin in patients with acute venous thromboembolism, according to data from the RE-COVER trial reported Dec. 6 at the American Society of Hematology meeting in New Orleans